# US 2010/0074946 A1 · Process for preparing purified nucleic acid and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074946 A1
- Document ID: US20100074946A1
- Status: Published application
- Kind: A1
- Application number: 12/627,449
- Filed: 2009-11-30
- Published: 2010-03-25
- Earliest claimed: 1996-02-06
- Assignees: Roche Diagnostics GmbH
- Inventors: Wolfgang KUHNE
- Web page: https://patentgrep.com/patent/US20100074946A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/16: Central respiratory analeptics
- C12N 15/101: {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- C12N 15/85: for animal cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)n and with a content of below 1EU/mg DNA of endotoxins. Said preparation is suitable as a drug particularly in gene therapy.

## Claims

### Claim 1

DNA preparation comprising a DNA, proteins in an amount of less than about 0.1% DNA and endotoxins in an amount of less than about 1 EU/mg DNA.

### Claim 2 (depends on 1)

The DNA preparation of claim 1, comprising endotoxins of less than about 0.06 EU/mg DNA.

### Claim 3 (depends on 1)

The DNA preparation of claim 1, comprising endotoxins of about 0.01 to 0.1 EU/mg DNA.

### Claim 4 (depends on 1)

The DNA preparation of claim 1, wherein the DNA preparation is free of ethidium bromide, phenol, cesium chloride, octylphenolpoly(ethylene glycol ether)n detergents and MOPS buffer.

### Claim 5 (depends on 1)

The DNA preparation of claim 1, wherein the DNA can be replicated in gram-negative bacteria.

### Claim 6 (depends on 15)

The DNA preparation of claim 15, wherein the gram-negative bacteria is Escherichia coli.

### Claim 7 (depends on 1)

The DNA preparation of claim 1, wherein the DNA is plasmid DNA.

### Claim 8 (depends on 7)

The DNA preparation of claim 7, wherein the plasmid DNA is capable of replication.

### Claim 9 (depends on 5)

A pharmaceutical composition suitable for gene therapy comprising a therapeutically effective amount of the DNA preparation of claim 5 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the DNA preparation contains endotoxins in an amount of less than about 0.06 EU/mg DNA.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the DNA preparation contains endotoxins in an amount of about 0.01 to 0.1 EU/mg DNA.

### Claim 12 (depends on 9)

The composition of claim 9, wherein the DNA is a plasmid DNA.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the plasmid DNA is encapsulated in liposomes.

### Claim 14 (depends on 18)

A method for gene therapy of cystic fibrosis caused by the absence of a normal first gene or the presence of a defective second gene, comprising administering an effective amount of the DNA preparation of claim 18 to a patient in need thereof, wherein the plasmid DNA contains said normal first gene or a normal second gene corresponding to the defective second gene.

### Claim 15 (depends on 1)

A process for making the DNA preparation of claim 1, comprising the following steps
(a) providing gram-negative bacteria containing said DNA;
(b) lysing said bacteria to obtain a lysate, wherein the lysate is a DNA-containing fraction and thereafter
(c) chromatographing said DNA-containing fraction on hydroxylapatite in order to obtain said DNA preparation.

### Claim 16 (depends on 15)

The method of claim 15, further comprising replicating said DNA in gram-negative bacteria after step (a) and before step (b).

### Claim 17 (depends on 16)

The method of claim 16, further comprising transfecting the gram-negative bacteria with a cloning vector containing said DNA before step (a).

### Claim 18 (depends on 16)

The method of claim 16, further comprising eluting said hydroxylapatite in step (c) with a solution of phosphate, citrate, sulfate or divalent metal ions to obtain said DNA preparation.

### Claim 19 (depends on 15)

The method of claim 15, further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.

### Claim 20 (depends on 16)

The method of claim 16, further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.

### Claim 21 (depends on 17)

The method of claim 17, further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.

### Claim 22 (depends on 18)

The method of claim 18, further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.
